KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 140 patients (estimated)
- Sponsors
- Keros Therapeutics, Inc.
- Tags
- Growth Factor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1646
- NCT Identifier
- NCT04419649
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.